WO2023156864 - PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2023/156864
Publication Date
24.08.2023
International Application No.
PCT/IB2023/050812
International Filing Date
31.01.2023
Title **
[English]
PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF
[French]
COMPOSÉS À BASE DE PYRIDAZINONE UTILISÉS EN TANT QU'INHIBITEURS D'AXL, C-MET ET MER ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
CMG PHARMACEUTICAL CO., LTD.
SUNGKWANG MEDICAL FOUNDATION
Inventors
KIM, Jin Sung
KIM, Sungmoo
JEONG, Ju Hui
AN, Hyun Sook
KIM, Soojeong
Priority Data
63/310,823
16.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3062 | |
| EPO | Filing, Examination, Granting | 17358 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 1879 | |
| USA | Filing, Examination, Granting | 5790 |
Total:
30,396
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.[French]
, G et Q sont décrits dans la description. L'invention concerne en outre une méthode de traitement ou de prévention d'une maladie médiée par AXL, Mer et/ou c-Met à l'aide d'une quantité efficace du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. Lorsque AXL, MER et/ou c-Met sont inhibé, le composé ou un sel pharmaceutiquement acceptable de celui-ci peut resensibiliser des cellules cancéreuses, telles que des cellules du cancer du poumon non à petites cellules, qui ont fait l'objet d'une croissance résistante à un agent anticancéreux.